Bristol-Myers Squibb Company (BMY)
Operating return on assets (Operating ROA)
| Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 | Dec 31, 2020 | Sep 30, 2020 | Jun 30, 2020 | Mar 31, 2020 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating income (ttm) | US$ in thousands | -12,354,000 | -11,456,000 | -11,502,000 | -11,251,000 | -9,504,000 | -10,337,000 | -10,597,000 | -9,851,000 | -10,280,000 | -12,331,000 | -12,539,000 | -14,016,000 | -15,487,000 | -1,800,000 | -2,410,000 | -3,043,000 | -3,317,000 | -6,022,000 | 1,007,000 | 4,789,000 |
| Total assets | US$ in thousands | 92,603,000 | 93,670,000 | 94,646,000 | 99,031,000 | 95,159,000 | 91,263,000 | 93,489,000 | 94,281,000 | 96,820,000 | 98,196,000 | 100,357,000 | 103,034,000 | 109,314,000 | 110,893,000 | 110,797,000 | 112,435,000 | 118,481,000 | 125,536,000 | 128,076,000 | 129,285,000 |
| Operating ROA | -13.34% | -12.23% | -12.15% | -11.36% | -9.99% | -11.33% | -11.34% | -10.45% | -10.62% | -12.56% | -12.49% | -13.60% | -14.17% | -1.62% | -2.18% | -2.71% | -2.80% | -4.80% | 0.79% | 3.70% |
December 31, 2024 calculation
Operating ROA = Operating income (ttm) ÷ Total assets
= $-12,354,000K ÷ $92,603,000K
= -13.34%
The operating return on assets (ROA) of Bristol-Myers Squibb Company has shown a declining trend over the period from March 31, 2020, to December 31, 2024. The operating ROA started at a relatively healthy level of 3.70% in March 2020 but gradually deteriorated.
There was a significant drop in operating ROA by September 2020, where it turned negative at -4.80%. The negative trend continued through the subsequent quarters, reaching its lowest point at -14.17% in December 2021.
Although there were fluctuations in the operating ROA in the following periods, the general trend remained negative, indicating that the company was not generating sufficient operating income relative to its asset base.
The declining operating ROA may suggest inefficiencies in the company's operations or challenges in generating profits from its assets. It is essential for Bristol-Myers Squibb Company to address the factors contributing to the decreasing ROA to improve its operational efficiency and profitability.
Peer comparison
Dec 31, 2024